


PHARMACEUTICAL 2022

ELI LILLY & Co Rank 76 of 475









PHARMACEUTICAL 2022

ELI LILLY & Co Rank 76 of 475



The relative strengths and weaknesses of ELI LILLY & Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI LILLY & Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 323% points. The greatest weakness of ELI LILLY & Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is 84%, being 360% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	18,452,400
Cost of Goods Sold	7,312,800
Intangible Assets	11,583,900
Liabilities, Current	15,052,700
Liabilities, Non-Current	24,598,500
Other Assets	9,784,600
Other Compr. Net Income	2,153,300
Other Expenses	1,966,400
Other Liabilities	0
Other Net Income	0
Property and Equipment	8,985,100
Research and Development	7,025,900
Revenues	28,318,400
Selling, General and Administrative Expense	6,431,600

Output Variable	Value in 1000 USD
Assets	48,806,000
Liabilities	39,651,200
Expenses	22,736,700
Stockholders Equity	9,154,800
Net Income	5,581,700
Comprehensive Net Income	6,658,350
Economic Capital Ratio	84%

